| |  Online-Ressource |
|---|
| Verfasst von: | Sahm, Katharina [VerfasserIn]  |
|---|
| | Ott, Martina [VerfasserIn] |
|---|
| | Bunse, Theresa [VerfasserIn] |
|---|
| | Sahm, Felix [VerfasserIn] |
|---|
| | Bunse, Lukas [VerfasserIn] |
|---|
| | Deumelandt, Katrin [VerfasserIn] |
|---|
| | Sonner, Jana K. [VerfasserIn] |
|---|
| | Keil, Melanie [VerfasserIn] |
|---|
| | Deimling, Andreas von [VerfasserIn] |
|---|
| | Wick, Wolfgang [VerfasserIn] |
|---|
| | Platten, Michael [VerfasserIn] |
|---|
| Titel: | K27M-mutant histone-3 as a novel target for glioma immunotherapy |
|---|
| Verf.angabe: | Katharina Ochs, Martina Ott, Theresa Bunse, Felix Sahm, Lukas Bunse, Katrin Deumelandt, Jana K. Sonner, Melanie Keil, Andreas von Deimling, Wolfgang Wick, Michael Platten |
|---|
| E-Jahr: | 2017 |
|---|
| Jahr: | 05 Jul 2017 |
|---|
| Umfang: | 7 S. |
|---|
| Fussnoten: | Gesehen am 25.04.2018 |
|---|
| Titel Quelle: | Enthalten in: OncoImmunology |
|---|
| Ort Quelle: | Abingdon : Taylor & Franics, 2012 |
|---|
| Jahr Quelle: | 2017 |
|---|
| Band/Heft Quelle: | 6(2017) Artikel-Nummer e1328340, 7 Seiten |
|---|
| ISSN Quelle: | 2162-402X |
|---|
| Abstract: | Mutation-specific vaccines have become increasingly important in glioma immunotherapy; however, shared neoepitopes are rare. For diffuse gliomas, a driver mutation in the gene for isocitrate dehydrogenase type-1 has been shown to produce an immunogenic epitope currently targeted in clinical trials. For highly aggressive midline gliomas, a recurrent point mutation in the histone-3 gene (H3F3A) causes an amino acid change from lysine to methionine at position 27 (K27M). Here, we demonstrate that a peptide vaccine against K27M-mutant histone-3 is capable of inducing effective, mutation-specific, cytotoxic T-cell- and T-helper-1-cell-mediated immune responses in a major histocompatibility complex (MHC)-humanized mouse model. By proving an immunologically effective presentation of the driver mutation H3K27M on MHC class II in human H3K27M-mutant gliomas, our data provide a basis for the further clinical development of vaccine-based or cell-based immunotherapeutic approaches targeting H3K27M. |
|---|
| DOI: | doi:10.1080/2162402X.2017.1328340 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: http://dx.doi.org/10.1080/2162402X.2017.1328340 |
|---|
| | Volltext: https://doi.org/10.1080/2162402X.2017.1328340 |
|---|
| | DOI: https://doi.org/10.1080/2162402X.2017.1328340 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Glioma |
|---|
| | K27M-mutant histone H3 |
|---|
| | neoepitope |
|---|
| | vaccination |
|---|
| K10plus-PPN: | 1572373261 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
K27M-mutant histone-3 as a novel target for glioma immunotherapy / Sahm, Katharina [VerfasserIn]; 05 Jul 2017 (Online-Ressource)
